AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8936627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg daily
Number of subjects: 80
Study 8936627 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone 50 mg daily
Number of subjects: 80
Study 8936627 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tamsulosin 0.2 mg and chlormadinone 50 mg daily
Number of subjects: 80
Study 8936627 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg and chlormadinone 50 mg daily
Number of subjects: 80
Study 8936627 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 80
Study 8447241 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 100
Study 8447241 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 100
Study 3532763 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal vaccine
Number of subjects: 1273
Study 29593013 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial hypercholesterolemia (FH)
Number of subjects: 106412
Study 29593013 — intervention group
Group type: EXPERIMENTAL
Intervention: High LDL cholesterol
Number of subjects: 106412
Study 29593013 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical FH criteria including personal premature ischemic heart disease
Number of subjects: 106412
Study 29593013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic heart disease at baseline
Number of subjects: 106412
Study 27538423 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lifestyle intervention (CLI) for 1 year
Number of subjects: 381
Study 27538423 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 381
Study 24116868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 489
Study 24116868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 489
Study 24116868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab dose adjustment to 90 mg
Number of subjects: 489
Study 24116868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (overall population)
Number of subjects: 489
Study 22717177 — intervention group
Group type: EXPERIMENTAL
Intervention: NRF education group
Number of subjects: 189
Study 22717177 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 189
Study 20298928 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 86
Study 20298928 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 86
Study 20298928 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 86
Study 20298928 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 86
Study 20298928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 18220486 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg b.i.d.
Number of subjects: 9
Study 18220486 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone 45 mg/day
Number of subjects: 9
Study 15819761 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine 2 mg
Number of subjects: 89
Study 15819761 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 10 mg
Number of subjects: 89
Study 15819761 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 89
Study 12640329 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue coloured placebo for anxious patients
Number of subjects: 34
Study 12640329 — intervention group
Group type: EXPERIMENTAL
Intervention: Red coloured placebo for tired patients
Number of subjects: 34
Study 9872878 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviewers asked to be identified
Number of subjects: 125
Study 9872878 — intervention group
Group type: COMPARATOR
Intervention: Anonymous reviewers
Number of subjects: 125
Study 9872878 — intervention group
Group type: EXPERIMENTAL
Intervention: Editors' quality score for reviews
Number of subjects: 125
Study 8951965 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (0.1 mg/70 kg)
Number of subjects: 12
Study 8951965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (0.5, 1, and 2 mg per 70 kg) with fentanyl
Number of subjects: 12
Study 8951965 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 8951965 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (combined with fentanyl)
Number of subjects: 12
Study 1937995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg intravenously every 8 hours for 3 days, then 150 mg orally in the evening for one month)
Number of subjects: 58
Study 1937995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 7380586 — intervention group
Group type: COMPARATOR
Intervention: Proquazone (600 mg) after 20 ml of antacid (Maaloxan)
Number of subjects: 12
Study 7380586 — intervention group
Group type: EXPERIMENTAL
Intervention: Proquazone (600 mg) after a standard breakfast
Number of subjects: 12
Study 31763228 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid based ointment with tablet Rupatidine 10 mg OD
Number of subjects: 60
Study 31763228 — intervention group
Group type: COMPARATOR
Intervention: Tablet Rupatidine 10 mg OD alone
Number of subjects: 60
Study 27029957 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric exercise (plate jump) during warm-up
Number of subjects: 10
Study 27029957 — intervention group
Group type: COMPARATOR
Intervention: No plyometric exercise during warm-up
Number of subjects: 10
Study 26300796 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based auditory training (CBAT) for 4 weeks, focusing on phoneme discrimination.
Number of subjects: 44
Study 23798058 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with bowel resection
Number of subjects: 203
Study 23798058 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery without bowel resection
Number of subjects: 203
Study 21232078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 61
Study 21232078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 61
Study 18999322 — intervention group
Group type: EXPERIMENTAL
Intervention: Welfare programs that increased maternal employment and family income
Number of subjects: 0
Study 17051119 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet plasma growth factors
Number of subjects: 20
Study 17051119 — intervention group
Group type: COMPARATOR
Intervention: Control areas (no treatment)
Number of subjects: 20
Study 12494247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 12494247 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial duration
Number of subjects: 35
Study 11078252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ethanol administration (60 ml of 100 proof ethanol)
Number of subjects: 18
Study 8985569 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive pre-coated brackets
Number of subjects: 38
Study 8985569 — intervention group
Group type: COMPARATOR
Intervention: No-mix adhesive (Control)
Number of subjects: 38
Study 1526058 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol spray (Otomize)
Number of subjects: 0
Study 6545095 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative explanation of the study
Number of subjects: 32
Study 6545095 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the study
Number of subjects: 32
Study 6545095 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing tests
Number of subjects: 32
Study 6545095 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to volunteer for future studies
Number of subjects: 32
Study 6545095 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of age and surgery on attitudes
Number of subjects: 32
Study 29984804 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor‐2 treatment
Number of subjects: 134
Study 29984804 — intervention group
Group type: COMPARATOR
Intervention: Observational group
Number of subjects: 134
Study 27709280 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-body computed tomography (TBCT)
Number of subjects: 1083
Study 27709280 — intervention group
Group type: COMPARATOR
Intervention: Standard work-up (STWU)
Number of subjects: 1083
Study 25663125 — intervention group
Group type: COMPARATOR
Intervention: CF-HAIC (Cisplatin 60 mg/m2 on day 2, 5-FU 500 mg/m2 on days 1-3)
Number of subjects: 56
Study 25663125 — intervention group
Group type: EXPERIMENTAL
Intervention: ACF-HAIC (Adriamycin 50 mg/m2 on day 1, Cisplatin 60 mg/m2 on day 2, 5-FU 500 mg/m2 on days 1-3)
Number of subjects: 56
Study 23282217 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour online self-regulation intervention
Number of subjects: 791
Study 23282217 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 791
Study 22027669 — intervention group
Group type: EXPERIMENTAL
Intervention: Topamax (topiramate) as mono-therapy (8 children) and combined therapy (22 children) with a mean treatment dose of 5.9 mg/kg per day
Number of subjects: 30
Study 22027669 — intervention group
Group type: EXPERIMENTAL
Intervention: Topamax (topiramate)
Number of subjects: 30
Study 18638266 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Negative Pressure (TNP) therapy
Number of subjects: 33
Study 18638266 — intervention group
Group type: COMPARATOR
Intervention: Conventional gauze therapy
Number of subjects: 33
Study 16619056 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin administration
Number of subjects: 15
Study 14508884 — intervention group
Group type: EXPERIMENTAL
Intervention: MBI-226 gel formulation
Number of subjects: 0
Study 11045863 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 128
Study 11045863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 9187996 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (4 x 10(‐12) to 1 x 10(‐4) mol/L)
Number of subjects: 0
Study 9187996 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (10(‐9) to 10(‐8) mol/L)
Number of subjects: 0
Study 9187996 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 1568371 — intervention group
Group type: EXPERIMENTAL
Intervention: Single i.v. administration of 2 g ceftazidime concurrent with anesthesia induction (group 1)
Number of subjects: 392
Study 1568371 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term prophylaxis with 1 g ceftazidime administered preanesthesia, 30 min before surgery and 6 and 12 hrs after the first dose (group 2)
Number of subjects: 392
Study 2859775 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 100 mg three times a day
Number of subjects: 21
Study 2859775 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg three times a day
Number of subjects: 21
Study 2859775 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 600 mg three times a day
Number of subjects: 21
Study 2859775 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 30 mg three times a day
Number of subjects: 21
Study 2859775 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 60 mg three times a day
Number of subjects: 21
Study 2859775 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 180 mg three times a day
Number of subjects: 21
Study 2859775 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 1 mg/kg infused over 15 minutes
Number of subjects: 21
Study 31763746 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVATE intervention (wearable-based intervention to increase physical activity and reduce sedentary behavior)
Number of subjects: 83
Study 31763746 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVATE intervention
Number of subjects: 83
Study 31763746 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 83
Study 29996854 — intervention group
Group type: EXPERIMENTAL
Intervention: ARMADILLO intervention providing SRH information via text message
Number of subjects: 0
Study 29996854 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no information
Number of subjects: 0
Study 29996854 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 3 with varying interactions by site (Kenya and Peru)
Number of subjects: 0
Study 27097970 — intervention group
Group type: EXPERIMENTAL
Intervention: DCs/CIKs combined with thoracic radiotherapy (TRT)
Number of subjects: 82
Study 27097970 — intervention group
Group type: COMPARATOR
Intervention: TRT alone
Number of subjects: 82
Study 27097970 — intervention group
Group type: EXPERIMENTAL
Intervention: DCs/CIKs combined with TRT
Number of subjects: 82
Study 24045444 — intervention group
Group type: EXPERIMENTAL
Intervention: Retaining outer gloves for 1 hour into the case
Number of subjects: 353
Study 24045444 — intervention group
Group type: COMPARATOR
Intervention: Exchanging outer gloves for 1 hour into the case
Number of subjects: 353
Study 24045444 — intervention group
Group type: COMPARATOR
Intervention: Cloth gowns
Number of subjects: 353
Study 24045444 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper gowns
Number of subjects: 353
Study 24045444 — intervention group
Group type: COMPARATOR
Intervention: Cloth gowns in strike-through study
Number of subjects: 353
Study 24045444 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper gowns in strike-through study
Number of subjects: 353
Study 22498020 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention program (adaptation of the asthma, sport and health program)
Number of subjects: 138
Study 22498020 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention program (after 3 months)
Number of subjects: 138
Study 22498020 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 138
Study 20980998 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly kisspeptin-54 (KP-54) injections for 8 weeks
Number of subjects: 0
Study 20980998 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily kisspeptin-54 (KP-54) injections
Number of subjects: 0
Study 20980998 — intervention group
Group type: COMPARATOR
Intervention: Saline treatment
Number of subjects: 0
Study 18591698 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (FA) 1 mg.kg(‐1) iv, 30 min before and six hours after skin incision
Number of subjects: 40
Study 17380846 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydropyridines (DHP) treatment
Number of subjects: 54
Study 15038587 — intervention group
Group type: EXPERIMENTAL
Intervention: R-ORS
Number of subjects: 113
Study 10809917 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+ IFNgamma mRNA expressing lymphocytes
Number of subjects: 0
Study 10809917 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+ IFNgamma mRNA expressing lymphocytes
Number of subjects: 0
Study 10809917 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+ and CD8+ IFNgamma mRNA expressing cells
Number of subjects: 0
Study 10809917 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 8646827 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat infusion in small dorsal hand veins at skin temperatures < 29.0 degrees C
Number of subjects: 0
Study 8646827 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat infusion in small dorsal hand veins at skin temperatures > 31 degrees C with norepinephrine preconstriction
Number of subjects: 0
Study 8646827 — intervention group
Group type: COMPARATOR
Intervention: Insulin-mediated vasodilation
Number of subjects: 0
Study 8646827 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin-mediated vasodilation
Number of subjects: 0
Study 1633323 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 300 mg daily
Number of subjects: 12
Study 1633323 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA 500 mg twice daily
Number of subjects: 12
Study 1633323 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg twice daily
Number of subjects: 12
Study 1633323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg twice daily
Number of subjects: 12
Study 6500225 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg four times a day
Number of subjects: 12
Study 6500225 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg four times a day
Number of subjects: 12
Study 6500225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31704789 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with continuous infusion of 0.2% levobupivacaine (8 mL/hour) after a 20 mL bolus.
Number of subjects: 88
Study 31704789 — intervention group
Group type: COMPARATOR
Intervention: Thoracic paravertebral block (TPVB) with continuous infusion of 0.2% levobupivacaine (8 mL/hour) after a 20 mL bolus.
Number of subjects: 88
Study 29190357 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive-behavioral therapy (CBT), 12 sessions of 50 minutes each over 6 months
Number of subjects: 273
Study 27631268 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery device
Number of subjects: 42
Study 27631268 — intervention group
Group type: COMPARATOR
Intervention: High-speed drill
Number of subjects: 42
Study 25104527 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 13642
Study 25104527 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban high dose
Number of subjects: 13642
Study 25104527 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban low dose
Number of subjects: 13642
Study 25104527 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label VKA
Number of subjects: 13642
Study 25104527 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label NOAC
Number of subjects: 13642
Study 22142173 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-lesson vegetable-focused intervention
Number of subjects: 1937
Study 22142173 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1937
Study 20598836 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 61
Study 20598836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 18056740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar cemented hemiarthroplasty
Number of subjects: 222
Study 18056740 — intervention group
Group type: COMPARATOR
Intervention: Internal fixation
Number of subjects: 222
Study 15891131 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 197
Study 15891131 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus artesunate (SP-AS)
Number of subjects: 197
Study 11788219 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma irradiation (iridium-192)
Number of subjects: 130
Study 11788219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 10090162 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA microemulsion (Neoral)
Number of subjects: 51
Study 10090162 — intervention group
Group type: COMPARATOR
Intervention: Conventional CyA (Sandimmun)
Number of subjects: 51
Study 7751734 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin (LFLX) 100 mg or 300 mg, administered as a single dose.
Number of subjects: 101
Study 2303583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen/codeine
Number of subjects: 0
Study 2303583 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin/codeine
Number of subjects: 0
Study 2303583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2303583 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatment groups (including ibuprofen/codeine and aspirin/codeine)
Number of subjects: 0
Study 7026247 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial prevention intervention
Number of subjects: 63732
Study 7026247 — intervention group
Group type: COMPARATOR
Intervention: Control group (factories not receiving intervention)
Number of subjects: 63732
Study 7026247 — intervention group
Group type: EXPERIMENTAL
Intervention: Belgium (intervention group)
Number of subjects: 63732
Study 7026247 — intervention group
Group type: EXPERIMENTAL
Intervention: Poland (intervention group)
Number of subjects: 63732
Study 30553570 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted A(H5N1) vaccine
Number of subjects: 0
Study 30553570 — intervention group
Group type: COMPARATOR
Intervention: Unadjuvanted A(H5N1) vaccine
Number of subjects: 0
Study 30553570 — intervention group
Group type: EXPERIMENTAL
Intervention: A(H5N1) vaccine antigen
Number of subjects: 0
Study 28386782 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mm × 9.0 mm screws for intermaxillary fixation (IMF)
Number of subjects: 56
Study 28386782 — intervention group
Group type: COMPARATOR
Intervention: 2.0 mm noncompression miniplates
Number of subjects: 56
Study 28386782 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 56
Study 25133644 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 hours after hCG injection
Number of subjects: 92
Study 25133644 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 hours after hCG injection
Number of subjects: 92
Study 25133644 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 hours after hCG injection
Number of subjects: 92
Study 23675676 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity
Number of subjects: 11140
Study 23675676 — intervention group
Group type: COMPARATOR
Intervention: No or mild physical activity
Number of subjects: 11140
Study 21546726 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure with omental patch
Number of subjects: 176
Study 21546726 — intervention group
Group type: COMPARATOR
Intervention: Only primary closure
Number of subjects: 176
Study 19366848 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone (NES) gel 2 mg
Number of subjects: 140
Study 19366848 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone (NES) gel 4 mg
Number of subjects: 140
Study 19366848 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) gel 10 g
Number of subjects: 140
Study 19366848 — intervention group
Group type: EXPERIMENTAL
Intervention: T gel 10 g plus NES gel 2 mg
Number of subjects: 140
Study 19366848 — intervention group
Group type: EXPERIMENTAL
Intervention: T gel 10 g plus NES gel 4 mg
Number of subjects: 140